慢性腎臓病市場：タイプ、適応症、エンドユーザー別-2025-2030年の世界予測

慢性腎臓病市場は、2023年に1,284億5,000万米ドルと評価され、2024年には1,365億6,000万米ドルに達すると予測され、CAGR 6.50％で成長し、2030年には1,996億4,000万米ドルに達すると予測されています。

慢性腎臓病（CKD）とは、糖尿病や高血圧などの要因によって世界的に数百万人が罹患している、腎臓の機能が徐々に失われることを特徴とする長期的な状態を指します。CKD市場には、医薬品、診断薬、透析器、腎移植が含まれ、ヘルスケア分野における重要な必要性を示しています。CKD管理には、早期診断、モニタリング、治療順守、専門クリニックへの相談が含まれ、医療従事者のニーズと患者の転帰向上の両方に対応します。最終用途のセグメンテーションでは、主に病院、診断研究所、研究機関に焦点を当てており、治療・診断手段の進歩を通じて市場の需要を牽引しています。CKD市場に影響を与える主な成長要因としては、糖尿病や高血圧の有病率の増加、診断・治療手技の技術進歩、政府の支援政策などが挙げられます。潜在的な機会は、患者の継続的なモニタリングを提供するための個別化医療と遠隔医療サービスの開発にあります。企業は、患者のアドヒアランスとモニタリングを強化し、満たされていない臨床ニーズに効果的に対応するために、AI主導の診断ツールやウェアラブルデバイスへの投資を検討すべきです。しかし、市場成長は、高額な治療費、規制上の課題、早期診断と治療アドヒアランスに関する患者の不十分な認識といった限界に直面しています。さらに、AI、機械学習、ブロックチェーンのような革新的技術の統合は、業務を合理化し、患者の診断精度を向上させ、安全な患者データ管理を促進する可能性があります。腎臓学の研究や、CKDに合わせた先進的なバイオ医薬品の開発も、事業の成長を促進する可能性があります。CKD市場は非常にダイナミックで消費者中心の市場であり、絶え間ないイノベーションと規制や技術の変化への適応が求められます。こうした進歩に歩調を合わせ、個別化医療とデジタルヘルス・ソリューションを通じて患者の予後改善に注力することで、市場での存在感と収益性を大幅に高めることができます。こうした要素を踏まえ、企業は戦略的提携や研究パートナーシップを優先し、新たな技術動向を効果的に活用する必要があります。

市場力学：急速に進化する慢性腎臓病市場の主要市場インサイトを公開

慢性腎臓病市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 高齢化に伴う慢性腎臓病の世界的普及率の上昇
  • ヘルスケアインフラの改善を目的とした政府および規制当局の支援政策
  • 腎臓疾患の早期スクリーニングと診断に関する一般市民と医療界の意識の高まり
• 市場抑制要因
  • 高コストと地域間の製品標準化のギャップ
• 市場機会
  • 治療・診断技術および製品イノベーションの進歩
  • 遠隔医療および遠隔モニタリング技術の拡大
• 市場の課題
  • 先進的腎臓病治療の商業化の制限

ポーターのファイブフォース：慢性腎臓病市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：慢性腎臓病市場における外部からの影響の把握

外部マクロ環境要因は、慢性腎臓病市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析慢性腎臓病市場における競合情勢の把握

慢性腎臓病市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス慢性腎臓病市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、慢性腎臓病市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨慢性腎臓病市場における成功への道筋を描く

慢性腎臓病市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 高齢化に伴い慢性腎臓病の世界の蔓延が増加
    • ヘルスケアインフラの改善を目的とした政府および規制の支援政策
    • 腎臓疾患の早期スクリーニングと診断に関する一般市民と医療コミュニティの意識の高まり
  • 抑制要因
    • 地域間での製品標準化における高コストとギャップ
  • 機会
    • 治療・診断技術の進歩と製品革新
    • 遠隔医療と遠隔モニタリング技術の拡大
  • 課題
    • 腎臓病の進行性治療の商業化は限定的
• 市場セグメンテーション分析
  • タイプ：腎臓の機能を判断するための慢性腎臓病診断ソリューションの必要性の高まり
  • エンドユーザー：病院やクリニックでは幅広いサービスが提供されており、慢性腎臓病治療へのアクセスが拡大しています。
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 慢性腎臓病市場：タイプ別

• 診断
  • 血液検査
  • 画像検査
  • 腎臓生検
  • 尿検査
• 治療
  • 透析
  • 腎臓移植
  • 薬物治療
    • ACE阻害薬
    • アンジオテンシン受容体遮断薬
    • ベータ遮断薬
    • 利尿剤
    • エリスロポエチン刺激剤
    • フィネレノン
    • グルカゴン様ペプチド-1受容体作動薬
    • インスリン
    • メトホルミン
    • カリウム結合剤
    • ナトリウム-グルコース共輸送体-2阻害剤
    • スタチン

第7章 慢性腎臓病市場適応症別

• 慢性間質性腎炎
• 糖尿病性腎症
• 糸球体腎炎
• 高血圧性腎症
• 閉塞性腎症
• 多発性嚢胞腎

第8章 慢性腎臓病市場：エンドユーザー別

• 外来手術センター
• 診断センターおよび検査室
• 病院・クリニック
• 専門治療センター

第9章 南北アメリカの慢性腎臓病市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の慢性腎臓病市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの慢性腎臓病市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • FDA、CKD患者の貧血治療としてアケビア・セラピューティクス社のVafseoを承認
  • FDAが慢性腎臓病治療薬Jardiance（R）を承認、非推奨用途を明記
  • シグニファイヘルス、メディケアアドバンテージ会員向けに在宅腎臓健康評価を開始
• 戦略分析と提言

企業一覧

• AbbVie Inc.
• Allmed Medical Products Co., Ltd.
• AngioDynamics, Inc.
• Apotex Inc.
• Asahi Kasei Corporation
• AstraZeneca PLC
• B. Braun SE
• Baxter International, Inc.
• Becton, Dickinson and Company
• Centessa Pharmaceuticals Limited
• DaVita Inc.
• Dialife SA
• Dr. Reddys Laboratories Ltd.
• Evoqua Water Technologies LLC
• Fresenius Medical Care AG
• Galapagos NV
• Hemoclean Co. Ltd.
• JMS Co., Ltd.
• Johnson & Johnson Services, Inc.
• Medtronic PLC
• Merck & Co., Inc.
• Nikkiso Co., Ltd.
• Nipro Corporation
• Novartis AG
• NxStage Medical Inc.
• Otsuka Pharmaceutical Co., Ltd.
• Reata Pharmaceuticals Inc.
• Rockwell Medical Inc.
• Sanofi S.A.
• Teva Pharmaceutical Industries Ltd.
• Toray Medical Co., Ltd.
• Trivitron Healthcare
• XORTX Therapeutics Inc.

LIST OF FIGURES

• FIGURE 1. CHRONIC KIDNEY DISEASE MARKET RESEARCH PROCESS
• FIGURE 2. CHRONIC KIDNEY DISEASE MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. CHRONIC KIDNEY DISEASE MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. CHRONIC KIDNEY DISEASE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. CHRONIC KIDNEY DISEASE MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. CHRONIC KIDNEY DISEASE MARKET DYNAMICS
• TABLE 7. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY KIDNEY BIOPSY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY URINE TESTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIALYSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY KIDNEY TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY ACE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY BETA BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIURETICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY ERYTHROPOIETIN STIMULANTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY FINERENONE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY INSULIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY METFORMIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY POTASSIUM BINDERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY STATINS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY CHRONIC INTERSTITIAL NEPHRITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIABETIC NEPHROPATHY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY GLOMERULONEPHRITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY HYPERTENSIVE NEPHROPATHY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY OBSTRUCTIVE NEPHROPATHY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY POLYCYSTIC KIDNEY DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 39. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 40. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 41. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSTIC CENTERS & LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 42. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 43. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY SPECIALITY TREATMENT CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 44. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 45. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 46. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 47. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 48. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 49. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 50. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 51. ARGENTINA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 52. ARGENTINA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 53. ARGENTINA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 54. ARGENTINA CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 55. ARGENTINA CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 56. ARGENTINA CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 57. BRAZIL CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 58. BRAZIL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 59. BRAZIL CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 60. BRAZIL CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 61. BRAZIL CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 62. BRAZIL CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 63. CANADA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 64. CANADA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 65. CANADA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 66. CANADA CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 67. CANADA CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 68. CANADA CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 69. MEXICO CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 70. MEXICO CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 71. MEXICO CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 72. MEXICO CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 73. MEXICO CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 74. MEXICO CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 75. UNITED STATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 76. UNITED STATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 77. UNITED STATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 78. UNITED STATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 79. UNITED STATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 80. UNITED STATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 81. UNITED STATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 82. ASIA-PACIFIC CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 83. ASIA-PACIFIC CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 84. ASIA-PACIFIC CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 85. ASIA-PACIFIC CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 86. ASIA-PACIFIC CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 87. ASIA-PACIFIC CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 88. ASIA-PACIFIC CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 89. AUSTRALIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 90. AUSTRALIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 91. AUSTRALIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 92. AUSTRALIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 93. AUSTRALIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 94. AUSTRALIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 95. CHINA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 96. CHINA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 97. CHINA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 98. CHINA CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 99. CHINA CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 100. CHINA CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 101. INDIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 102. INDIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 103. INDIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 104. INDIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 105. INDIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 106. INDIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 107. INDONESIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 108. INDONESIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 109. INDONESIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 110. INDONESIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 111. INDONESIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 112. INDONESIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 113. JAPAN CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 114. JAPAN CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 115. JAPAN CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 116. JAPAN CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 117. JAPAN CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 118. JAPAN CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 119. MALAYSIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 120. MALAYSIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 121. MALAYSIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 122. MALAYSIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 123. MALAYSIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 124. MALAYSIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 125. PHILIPPINES CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 126. PHILIPPINES CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 127. PHILIPPINES CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 128. PHILIPPINES CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 129. PHILIPPINES CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 130. PHILIPPINES CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 131. SINGAPORE CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 132. SINGAPORE CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 133. SINGAPORE CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 134. SINGAPORE CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 135. SINGAPORE CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 136. SINGAPORE CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 137. SOUTH KOREA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 138. SOUTH KOREA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 139. SOUTH KOREA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 140. SOUTH KOREA CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 141. SOUTH KOREA CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 142. SOUTH KOREA CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 143. TAIWAN CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 144. TAIWAN CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 145. TAIWAN CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 146. TAIWAN CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 147. TAIWAN CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 148. TAIWAN CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 149. THAILAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 150. THAILAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 151. THAILAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 152. THAILAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 153. THAILAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 154. THAILAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 155. VIETNAM CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 156. VIETNAM CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 157. VIETNAM CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 158. VIETNAM CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 159. VIETNAM CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 160. VIETNAM CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 161. EUROPE, MIDDLE EAST & AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 162. EUROPE, MIDDLE EAST & AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 163. EUROPE, MIDDLE EAST & AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 164. EUROPE, MIDDLE EAST & AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 165. EUROPE, MIDDLE EAST & AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 166. EUROPE, MIDDLE EAST & AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 167. EUROPE, MIDDLE EAST & AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 168. DENMARK CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 169. DENMARK CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 170. DENMARK CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 171. DENMARK CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 172. DENMARK CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 173. DENMARK CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 174. EGYPT CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 175. EGYPT CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 176. EGYPT CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 177. EGYPT CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 178. EGYPT CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 179. EGYPT CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 180. FINLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 181. FINLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 182. FINLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 183. FINLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 184. FINLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 185. FINLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 186. FRANCE CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 187. FRANCE CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 188. FRANCE CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 189. FRANCE CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 190. FRANCE CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 191. FRANCE CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 192. GERMANY CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 193. GERMANY CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 194. GERMANY CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 195. GERMANY CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 196. GERMANY CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 197. GERMANY CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 198. ISRAEL CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 199. ISRAEL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 200. ISRAEL CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 201. ISRAEL CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 202. ISRAEL CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 203. ISRAEL CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 204. ITALY CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 205. ITALY CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 206. ITALY CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 207. ITALY CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 208. ITALY CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 209. ITALY CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 210. NETHERLANDS CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 211. NETHERLANDS CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 212. NETHERLANDS CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 213. NETHERLANDS CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 214. NETHERLANDS CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 215. NETHERLANDS CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 216. NIGERIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 217. NIGERIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 218. NIGERIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 219. NIGERIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 220. NIGERIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 221. NIGERIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 222. NORWAY CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 223. NORWAY CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 224. NORWAY CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 225. NORWAY CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 226. NORWAY CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 227. NORWAY CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 228. POLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 229. POLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 230. POLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 231. POLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 232. POLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 233. POLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 234. QATAR CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 235. QATAR CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 236. QATAR CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 237. QATAR CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 238. QATAR CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 239. QATAR CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 240. RUSSIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 241. RUSSIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 242. RUSSIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 243. RUSSIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 244. RUSSIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 245. RUSSIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 246. SAUDI ARABIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 247. SAUDI ARABIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 248. SAUDI ARABIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 249. SAUDI ARABIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 250. SAUDI ARABIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 251. SAUDI ARABIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 252. SOUTH AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 253. SOUTH AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 254. SOUTH AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 255. SOUTH AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 256. SOUTH AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 257. SOUTH AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 258. SPAIN CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 259. SPAIN CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 260. SPAIN CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 261. SPAIN CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 262. SPAIN CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 263. SPAIN CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 264. SWEDEN CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 265. SWEDEN CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 266. SWEDEN CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 267. SWEDEN CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 268. SWEDEN CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 269. SWEDEN CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 270. SWITZERLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 271. SWITZERLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 272. SWITZERLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 273. SWITZERLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 274. SWITZERLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 275. SWITZERLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 276. TURKEY CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 277. TURKEY CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 278. TURKEY CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 279. TURKEY CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 280. TURKEY CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 281. TURKEY CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 282. UNITED ARAB EMIRATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 283. UNITED ARAB EMIRATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 284. UNITED ARAB EMIRATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 285. UNITED ARAB EMIRATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 286. UNITED ARAB EMIRATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 287. UNITED ARAB EMIRATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 288. UNITED KINGDOM CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 289. UNITED KINGDOM CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 290. UNITED KINGDOM CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 291. UNITED KINGDOM CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
• TABLE 292. UNITED KINGDOM CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 293. UNITED KINGDOM CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 294. CHRONIC KIDNEY DISEASE MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 295. CHRONIC KIDNEY DISEASE MARKET, FPNV POSITIONING MATRIX, 2023

The Chronic Kidney Disease Market was valued at USD 128.45 billion in 2023, expected to reach USD 136.56 billion in 2024, and is projected to grow at a CAGR of 6.50%, to USD 199.64 billion by 2030.

Chronic Kidney Disease (CKD) refers to a long-term condition characterized by gradual loss of kidney function, affecting millions globally due to factors such as diabetes and hypertension. The market scope includes pharmaceuticals, diagnostics, dialyzers, and renal transplantation, marking a critical necessity in the healthcare sector. CKD management involves early diagnosis, monitoring, treatment adherence, and consulting specialized clinics, addressing both healthcare providers' needs and enhancing patient outcomes. The end-use segmentation primarily focuses on hospitals, diagnostic laboratories, and research institutes, driving market demand through advancements in therapeutic and diagnostic measures. Key growth factors influencing the CKD market include increasing prevalence of diabetes and hypertension, technological advancements in diagnostic and treatment procedures, and supportive governmental policies. Potential opportunities lie in developing personalized medicine and telehealth services to provide continuous patient monitoring. Companies should consider investments in AI-driven diagnostic tools and wearable devices to enhance patient adherence and monitoring, addressing unmet clinical needs effectively. However, market growth faces limitations such as high treatment costs, regulatory challenges, and inadequate awareness among patients about early diagnosis and treatment adherence. Furthermore, the integration of innovative technologies like AI, machine learning, and blockchain could streamline operations, improve patient diagnosis accuracy, and facilitate secure patient data management. Research into nephrology and development of advanced biopharmaceuticals tailored for CKD can also propel business growth. The CKD market is highly dynamic and consumer-centric, demanding constant innovation and adaptation to regulatory and technological changes. Keeping pace with these advancements and focusing on improving patient outcomes through personalized care and digital health solutions can significantly enhance market presence and profitability. In light of these factors, companies should prioritize strategic collaborations and research partnerships to harness emerging technological trends effectively.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Chronic Kidney Disease Market

The Chronic Kidney Disease Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing global prevalence of chronic kidney disease with the aging population
  • Supportive government and regulatory policies aimed at improving healthcare infrastructure
  • Growing public and medical community awareness regarding early screening and diagnosis of kidney ailments
• Market Restraints
  • High cost and gap in product standardization across regions
• Market Opportunities
  • Advancements in treatment and diagnostic technologies and product innovation
  • Expansion of telemedicine and remote monitoring technologies
• Market Challenges
  • Limited commercialization of advanced kidney disease treatments

Porter's Five Forces: A Strategic Tool for Navigating the Chronic Kidney Disease Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Chronic Kidney Disease Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Chronic Kidney Disease Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Chronic Kidney Disease Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Chronic Kidney Disease Market

A detailed market share analysis in the Chronic Kidney Disease Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Chronic Kidney Disease Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Chronic Kidney Disease Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Chronic Kidney Disease Market

A strategic analysis of the Chronic Kidney Disease Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Chronic Kidney Disease Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Allmed Medical Products Co., Ltd., AngioDynamics, Inc., Apotex Inc., Asahi Kasei Corporation, AstraZeneca PLC, B. Braun SE, Baxter International, Inc., Becton, Dickinson and Company, Centessa Pharmaceuticals Limited, DaVita Inc., Dialife SA, Dr. Reddys Laboratories Ltd., Evoqua Water Technologies LLC, Fresenius Medical Care AG, Galapagos NV, Hemoclean Co. Ltd., JMS Co., Ltd., Johnson & Johnson Services, Inc., Medtronic PLC, Merck & Co., Inc., Nikkiso Co., Ltd., Nipro Corporation, Novartis AG, NxStage Medical Inc., Otsuka Pharmaceutical Co., Ltd., Reata Pharmaceuticals Inc., Rockwell Medical Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., Toray Medical Co., Ltd., Trivitron Healthcare, and XORTX Therapeutics Inc..

Market Segmentation & Coverage

This research report categorizes the Chronic Kidney Disease Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Diagnosis and Treatment. The Diagnosis is further studied across Blood Tests, Imaging Tests, Kidney Biopsy, and Urine Tests. The Treatment is further studied across Dialysis, Kidney Transplant, and Medication. The Medication is further studied across ACE Inhibitors, Angiotensin Receptor Blockers, Beta Blockers, Diuretics, Erythropoietin Stimulants, Finerenone, Glucagon-like Peptide-1 Receptor Agonists, Insulin, Metformin, Potassium Binders, Sodium-glucose Cotransporter-2 Inhibitors, and Statins.
• Based on Indication, market is studied across Chronic Interstitial Nephritis, Diabetic Nephropathy, Glomerulonephritis, Hypertensive Nephropathy, Obstructive Nephropathy, and Polycystic Kidney Disease.
• Based on End-User, market is studied across Ambulatory Surgery Centers, Diagnostic Centers & Laboratories, Hospitals & Clinics, and Speciality Treatment Centers.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing global prevalence of chronic kidney disease with the aging population
    • 5.1.1.2. Supportive government and regulatory policies aimed at improving healthcare infrastructure
    • 5.1.1.3. Growing public and medical community awareness regarding early screening and diagnosis of kidney ailments
  • 5.1.2. Restraints
    • 5.1.2.1. High cost and gap in product standardization across regions
  • 5.1.3. Opportunities
    • 5.1.3.1. Advancements in treatment and diagnostic technologies and product innovation
    • 5.1.3.2. Expansion of telemedicine and remote monitoring technologies
  • 5.1.4. Challenges
    • 5.1.4.1. Limited commercialization of advanced kidney disease treatments
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Growing need for chronic kidney disease diagnosis solutions to determine the function of the kidneys
  • 5.2.2. End-User: Growing accessibility of chronic kidney disease treatments through hospitals & clinics as they offer a broad range of services
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Chronic Kidney Disease Market, by Type

• 6.1. Introduction
• 6.2. Diagnosis
  • 6.2.1. Blood Tests
  • 6.2.2. Imaging Tests
  • 6.2.3. Kidney Biopsy
  • 6.2.4. Urine Tests
• 6.3. Treatment
  • 6.3.1. Dialysis
  • 6.3.2. Kidney Transplant
  • 6.3.3. Medication
    • 6.3.3.1. ACE Inhibitors
    • 6.3.3.2. Angiotensin Receptor Blockers
    • 6.3.3.3. Beta Blockers
    • 6.3.3.4. Diuretics
    • 6.3.3.5. Erythropoietin Stimulants
    • 6.3.3.6. Finerenone
    • 6.3.3.7. Glucagon-like Peptide-1 Receptor Agonists
    • 6.3.3.8. Insulin
    • 6.3.3.9. Metformin
    • 6.3.3.10. Potassium Binders
    • 6.3.3.11. Sodium-glucose Cotransporter-2 Inhibitors
    • 6.3.3.12. Statins

7. Chronic Kidney Disease Market, by Indication

• 7.1. Introduction
• 7.2. Chronic Interstitial Nephritis
• 7.3. Diabetic Nephropathy
• 7.4. Glomerulonephritis
• 7.5. Hypertensive Nephropathy
• 7.6. Obstructive Nephropathy
• 7.7. Polycystic Kidney Disease

8. Chronic Kidney Disease Market, by End-User

• 8.1. Introduction
• 8.2. Ambulatory Surgery Centers
• 8.3. Diagnostic Centers & Laboratories
• 8.4. Hospitals & Clinics
• 8.5. Speciality Treatment Centers

9. Americas Chronic Kidney Disease Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Chronic Kidney Disease Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Chronic Kidney Disease Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. FDA Approves Akebia Therapeutics' Vafseo for Treatment of Anemia in CKD Patients
  • 12.3.2. FDA Approves Jardiance(R) for Chronic Kidney Disease, Specifies Non-Recommended Uses
  • 12.3.3. Signify Health Launches In-Home Kidney Health Evaluations for Medicare Advantage Members
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Allmed Medical Products Co., Ltd.
• 3. AngioDynamics, Inc.
• 4. Apotex Inc.
• 5. Asahi Kasei Corporation
• 6. AstraZeneca PLC
• 7. B. Braun SE
• 8. Baxter International, Inc.
• 9. Becton, Dickinson and Company
• 10. Centessa Pharmaceuticals Limited
• 11. DaVita Inc.
• 12. Dialife SA
• 13. Dr. Reddys Laboratories Ltd.
• 14. Evoqua Water Technologies LLC
• 15. Fresenius Medical Care AG
• 16. Galapagos NV
• 17. Hemoclean Co. Ltd.
• 18. JMS Co., Ltd.
• 19. Johnson & Johnson Services, Inc.
• 20. Medtronic PLC
• 21. Merck & Co., Inc.
• 22. Nikkiso Co., Ltd.
• 23. Nipro Corporation
• 24. Novartis AG
• 25. NxStage Medical Inc.
• 26. Otsuka Pharmaceutical Co., Ltd.
• 27. Reata Pharmaceuticals Inc.
• 28. Rockwell Medical Inc.
• 29. Sanofi S.A.
• 30. Teva Pharmaceutical Industries Ltd.
• 31. Toray Medical Co., Ltd.
• 32. Trivitron Healthcare
• 33. XORTX Therapeutics Inc.